Annexon 将来の成長
Future 基準チェック /56
Annexonは、63%と60.7%でそれぞれ年率63%で利益と収益が成長すると予測される一方、EPSはgrowで63.9%年率。
主要情報
63.0%
収益成長率
63.88%
EPS成長率
| Biotechs 収益成長 | 25.2% |
| 収益成長率 | 60.7% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Good |
| 最終更新日 | 13 May 2026 |
今後の成長に関する最新情報
Recent updates
分析記事 • Apr 01
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...Seeking Alpha • Jan 24
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated Diseases
Summary Annexon offers high-risk, high-reward potential with its C1q-targeted pipeline, led by tanruprubart for GBS and vonaprument for geographic atrophy. Tanruprubart’s Phase III results are promising, but there is U.S. regulatory uncertainty due to non-U.S. trial sites and dose-response questions. Vonaprument’s Phase III trial focuses on vision preservation, potentially differentiating ANNX in the competitive but large geographic atrophy market. I estimate fair value at $14.50/share, with 2026 as a pivotal year for clarity on the tanruprubart filing process, clinical vonaprument milestones, and possible commercial partnerships. Read the full article on Seeking Alpha分析記事 • Oct 28
Is Annexon (NASDAQ:ANNX) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Jul 03
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Mar 13
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash
Summary Annexon’s lead candidate, ANX005, shows promise for treating Guillain-Barré Syndrome, achieving significant improvement in muscle strength and disability in phase 3 trials. Despite setbacks with ANX007 in Geographic Atrophy, the FDA approved a phase 3 trial focusing on vision preservation, with promising preliminary data. Financially, Annexon has a strong cash position, providing a runway of 5-8 quarters, but the stock trades almost at cash due to market skepticism. Risks include the ex-US trial locations for GBS and high short interest, but upcoming catalysts and a solid cash balance warrant close monitoring. Read the full article on Seeking Alpha分析記事 • Mar 10
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Seeking Alpha • Jan 08
Annexon: Breakthrough In Guillain-Barré Faces Upcoming FDA Hurdles
Summary Annexon, Inc. trades at ~$5.05, down ~22% since my last article in April 2024, indicating ongoing investor skepticism. The Q3 2024 earnings release and 10-Q reveal mixed prospects, impacting investor confidence. Positive topline data from real-world evidence in Guillain-Barré syndrome presented in December 2024 offer a potential catalyst for future growth. Its decision to conduct its clinical trials in Asia creates a potential point of friction for an FDA approval. Read the full article on Seeking Alpha分析記事 • Sep 27
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 17
Speculative "Buy" Rating On Annexon: Evaluating The Potential Of ANX005 For GBS
Summary Annexon’s ANX005 shows promise for GBS. Phase 3 trial results indicate expedited recovery and durable benefits. ANNX targets the classical complement pathway, specifically the C1q protein, to address autoimmune, neurodegenerative, and ophthalmic conditions. The company’s pipeline includes ANX005, ANX007, and ANX1502. Due to its advanced development stage, ANX005 is the primary value driver. Financially, ANNX has a strong cash position and a 4.2-year runway, supporting further development towards a potential FDA approval for ANX005. While ANX005 is promising, its effectiveness is crucial compared to current GBS treatments, with upcoming comparability data being a key factor. Read the full article on Seeking AlphaSeeking Alpha • Jun 04
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Summary Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025. If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025. ANX007 is another C1q inhibitor in the pipeline, which is being developed to treat patients with geographic atrophy. Read the full article on Seeking AlphaSeeking Alpha • Apr 03
Annexon: Unforced Error Sullies Prospects
Summary Annexon, Inc. is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. ANX005 has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS). GBS is a rare disease that affects patients in different ways. Read the full article on Seeking Alpha分析記事 • Nov 10
Here's Why We're Watching Annexon's (NASDAQ:ANNX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Jul 25
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Apr 11
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Feb 14
Are Investors Undervaluing Annexon, Inc. (NASDAQ:ANNX) By 25%?
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Annexon, Inc...分析記事 • Dec 28
We Think Annexon (NASDAQ:ANNX) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 16
Annexon started as a buy at Jefferies on market potential of candidates, data catalysts
Jefferies has initiated Annexion (NASDAQ:ANNX) with a buy rating saying that the company's candidates for conditions including Huntington's disease, Guillain-Barre Syndrome, and geographic atrophy are promising and have a large market potential. The firm has a $12 price target (~89% upside based on Thursday's close). Analyst Suji Jeong said that candidate ANX005 for Huntington's disease ("HD") has the potential to become the first disease-modifying therapy for the condition. It is currently in phase 2 for that indication. Jeong sets peak sales estimates of ANX005 in HD in the US and Europe at ~$400M. On ANX007 for geographic atrophy, currently in phase 2, Jeong wrote that it could address a market of 245K in the US. The analyst sees peak sales of ~$420M. Seeking Alpha's Quant Rating views Annexon (ANNX) as a buy with strong grades for momentum, growth, and revisions.Seeking Alpha • Aug 21
Annexon: A First Take
Shares of clinical-stage biopharma Annexon are down by half since an early January 2022 data release revealed 5 of 28 patients dropped out of a Phase 2 Huntington’s disease study. Despite this setback, its lead candidate ANX005 appears to be efficacious and has been generally well-tolerated in studies encompassing 170 patients. With a market cap close to cash on hand after a private placement and multiple shots on goal, the recent insider buying warranted further investigation. A full investment analysis and recommendation follow in the paragraphs below. Failure is the condiment that gives success its flavor.”― Truman Capote Today, we take an in-depth look at a small biotech concern that had a recent setback but still has some 'shots on goal'. An analysis follows below. Seeking Alpha Company Overview: Annexon, Inc. (ANNX) is a Brisbane, California based clinical-stage biopharmaceutical concern focused on the development of therapies that treat complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company has three clinical assets, all of which target the initiating molecule of the classical complement pathway: C1q. Annexon was formed in 2011 and went public in 2020, raising net proceeds of $262.4 million at $17 per share. The stock currently trades around $5.50 a share, translating to a market cap of approximately $360 million including recently issued warrants. Complement System For those unfamiliar, the complement system is part of the body’s immune system and is responsible for aiding in the elimination of microbes and damaged cells through three pathways: the classical complement; the alternative complement; and the lectin. Comprised of proteins produced by the liver, overactivation of the classical complement pathway can cause severe immune and inflammatory disorders. C1q is a protein complex that is part of the classical complement pathway and is activated when it binds specific antigen-antibody complexes. When overactivated, it triggers a powerful inflammatory cascade through the instigation of downstream pathway components that can cause tissue-damaging diseases. Annexon’s precision medicine platform is designed to produce C1q targeting compounds to block the early inflammatory cascade while preserving the beneficial immune functions of the lectin and alternative complement pathways critical to the clearance of pathogens and damaged cells. Pipeline From this platform Annexon has developed three clinical assets. ANX005. The company’s lead candidate is ANX005, an intravenously administered monoclonal antibody designed to fully inhibit C1q throughout the body and across the blood brain barrier to combat autoimmune and neurodegenerative diseases. It is currently undergoing evaluation in four clinical trials, the most advanced of which is a Phase 2/3 clinical study for the treatment of Guillain-Barre Syndrome [GBS], a rare, acute, autoimmune disease damaging the peripheral nervous system of ~15,000 patients in North America and Europe with no approved therapies. The 180-patient, placebo-controlled trial is expected to readout in 2023 with primary endpoint change from baseline in GBS Disability Scale. In a completed Phase 1b study, ANX005 was well-tolerated and achieved C1q suppression in both the peripheral and central nervous systems. However, ANX005’s Phase 2 study for Huntington’s disease [HD] has been the subject of significant concern after an interim readout in early January 2022 revealed that despite half of the 28 patients in the trial (at that time) experiencing clinical improvement in disease progression, five discontinued treatment, which somewhat contradicted the company’s assertion that ANX005 had been generally well-tolerated. Shares of ANNX fell 34% to $7.26 in the subsequent trading session, initiating a crash into the mid-2s. A June 7th, 2022 data readout indicated that disease progression was stabilized in the overall HD population during both the six months of treatment and the three-month follow-up period. Nine of twelve patients with high complement levels demonstrated improvement at week 24 and maintained it through week 36. Furthermore, a biomarker for synapse loss remained generally consistent over the nine-month study period. Most importantly, no one else dropped from the study and the three patients determined to have developed treatment-related side effects had those events improve or resolve after discontinuation. All three cases were in patients with elevated antinuclear antibody (ANA) titers at baseline. No patient with normal ANA titers experienced a severe adverse event. HD is a hereditary neurodegenerative disorder characterized by abnormal involuntary movements, progressive dementia, depression, and psychosis. In HD, C1q inappropriately tags synapses in the brain, sparking their destruction, inducing neurodegeneration. Onset of symptoms typically occurs between 30 to 50 years of age with death from cardio-respiratory complications approximately 10 to 20 years thereafter. Although there is medication to treat some of HD’s symptoms, there are no remedies that address its root cause for the ~30,000 Americans (80,000 globally) afflicted. The early June readout somewhat validated Annexon’s precision medicine approach and triggered a 25% one-day rally to $4.06 a share. This news was later used to execute a private placement – more on that below. ANX005 is also being studied in a Phase 2 trial for the treatment of warm autoimmune hemolytic anemia (AIHA), a malady characterized by the presence of auto-antibodies that bind to red blood cells. The temperature at which the binding occurs determines the warm or cold designation. Warm AIHA affects ~30,000 patients globally, with ~11% progressing to death. Data from the trial are anticipated in 2H22. Finally, ANX005 is undergoing Phase 2 assessment in the treatment of amyotrophic lateral sclerosis (ALS), the infamous devastating neurodegenerative disease that afflicts ~30,000 patients worldwide. A readout from the study is expected in 2023. The therapy has received Orphan Drug status from the FDA for GBS and HD as well as Fast Track designation for GBS. ANX007. Annexon’s other asset in a Phase 2 trial is ANX007, a formulation of an antigen-binding fragment [FAB] that is designed to inhibit C1q locally in the eye (initially) for patients with geographic atrophy [GA]. Also known as atrophic age-related macular degeneration, GA affects more than 5 million worldwide and has no approved treatment options. Topline data for the intravitreally administered therapy is expected in 1H23. ANX009. The company is also investigating ANX009, a subcutaneous formulation of a Fab designed to inhibit C1q only in the vascular space for the treatment of lupus nephritis. An ongoing Phase 1b trial is expected to produce initial data sometime in 2H22. Balance Sheet & Analyst Commentary: Management elected to leverage the somewhat positive news from the HD trial into a very dilutive capital raise, executing a private placement that raised gross proceeds of $130 million, consisting of common stock and pre-funded warrants representing 33.7 million shares at a price of ~$3.87, essentially doubling the total shares outstanding. Additionally, 8.4 million three-year common warrants with an exercise price of ~$5.81 were issued. This transaction, which closed on July 11, 2022, increased Annexon’s cash position to ~$300 million with no debt, providing it an operating runway into 2H25.Seeking Alpha • Aug 08
Annexon Biosciences GAAP EPS of -$0.96 misses by $0.02
Annexon Biosciences press release (NASDAQ:ANNX): Q2 GAAP EPS of -$0.96 misses by $0.02. Cash and cash equivalents and short-term investments were $177.6 million as of June 30, 2022, which does not include the approximately $130 million in gross proceeds from the company’s recently completed private placement.Seeking Alpha • Jul 08
Annexon to raise $130M in stock and warrant offering
Annexon (NASDAQ:ANNX) entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of ~$130M. The company is selling 9.01M shares, pre-funded warrants to purchase up to 24.7M shares and accompanying warrants to purchase up to 8.4M shares at a combined price of $3.87/share of stock and accompanying warrant and $3.87 for pre-funded warrant and accompanying common warrant. The accompanying common warrants will have an exercise price of $5.8/share and will be immediately exercisable and expire on June 30, 2025. Offer is expected to close on July 11, 2022. Shares trading 3.3% higher premarket.分析記事 • Apr 16
We're Keeping An Eye On Annexon's (NASDAQ:ANNX) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Jan 01
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Sep 08
Companies Like Annexon (NASDAQ:ANNX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 289 | 39 | -76 | 99 | 7 |
| 12/31/2027 | 41 | -175 | -141 | -188 | 10 |
| 12/31/2026 | N/A | -185 | -164 | -172 | 10 |
| 3/31/2026 | N/A | -198 | -183 | -183 | N/A |
| 12/31/2025 | N/A | -209 | -186 | -186 | N/A |
| 9/30/2025 | N/A | -209 | -177 | -176 | N/A |
| 6/30/2025 | N/A | -189 | -156 | -156 | N/A |
| 3/31/2025 | N/A | -167 | -140 | -140 | N/A |
| 12/31/2024 | N/A | -138 | -118 | -118 | N/A |
| 9/30/2024 | N/A | -118 | -105 | -105 | N/A |
| 6/30/2024 | N/A | -115 | -102 | -102 | N/A |
| 3/31/2024 | N/A | -121 | -116 | -116 | N/A |
| 12/31/2023 | N/A | -134 | -121 | -121 | N/A |
| 9/30/2023 | N/A | -141 | -125 | -125 | N/A |
| 6/30/2023 | N/A | -143 | -128 | -127 | N/A |
| 3/31/2023 | N/A | -145 | -120 | -119 | N/A |
| 12/31/2022 | N/A | -142 | -123 | -116 | N/A |
| 9/30/2022 | N/A | -145 | -125 | -117 | N/A |
| 6/30/2022 | N/A | -145 | -124 | -116 | N/A |
| 3/31/2022 | N/A | -140 | -120 | -113 | N/A |
| 12/31/2021 | N/A | -130 | -108 | -106 | N/A |
| 9/30/2021 | N/A | -116 | -98 | -97 | N/A |
| 6/30/2021 | N/A | -103 | -81 | -81 | N/A |
| 3/31/2021 | N/A | -84 | -67 | -67 | N/A |
| 12/31/2020 | N/A | -70 | -54 | -53 | N/A |
| 9/30/2020 | N/A | -56 | -43 | -43 | N/A |
| 6/30/2020 | N/A | -45 | -36 | -36 | N/A |
| 3/31/2020 | N/A | -42 | -33 | -32 | N/A |
| 12/31/2019 | N/A | -38 | N/A | -28 | N/A |
| 9/30/2019 | N/A | -34 | N/A | -24 | N/A |
| 6/30/2019 | N/A | -28 | N/A | -21 | N/A |
| 3/31/2019 | N/A | -23 | N/A | -19 | N/A |
| 12/31/2018 | N/A | -18 | N/A | -17 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: ANNXは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。
収益対市場: ANNX今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: ANNX今後 3 年以内に収益を上げることが予想されます。
収益対市場: ANNXの収益 ( 60.7% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: ANNXの収益 ( 60.7% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: ANNXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/15 20:47 |
| 終値 | 2026/05/15 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Annexon, Inc. 10 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13
| アナリスト | 機関 |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Thomas Shrader | BTIG |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |